Testosterone replacement therapy does not disqualify a commercial driver from passing a Department of Transportation (DOT) physical. No federal regulation lists testosterone as a prohibited substance or hypogonadism as a disqualifying medical condition.
At Longevity Benchmark, the guides we publish start from the primary source, which here is the regulation itself rather than the summaries of it that circulate in the trade. A commercial driver's license (CDL) holder may legally use testosterone replacement therapy (TRT) if the treatment satisfies the federal prescription exception. That exception requires a valid prescription from a licensed healthcare practitioner who knows the driver's medical history and confirms the therapy does not impair safe commercial vehicle operation.
The Verdict
TRT and DOT Physical Standards under Federal Regulations
Federal motor carrier safety regulations do not classify testosterone replacement therapy or low testosterone as disqualifying conditions for commercial drivers. The physical qualification standards governing commercial drivers are codified in 49 CFR 391.41. The complete list of disqualifying conditions appears across thirteen numbered subsections, from 391.41(b)(1) to 391.41(b)(13), and testosterone appears nowhere in that text.
The subsections that do disqualify a driver name specific conditions, and 49 CFR 391.41(b)(12)(i) sets an absolute bar on Schedule I substances, amphetamines, narcotics and other habit-forming drugs. Testosterone is not Schedule I, so the prescription exception in (b)(12)(ii) is available to it. Endocrine disorders like hypogonadism require clinical evaluation rather than automatic removal from service. Drivers pursuing therapy for signs of low testosterone do not violate federal qualification standards simply by beginning treatment.
The Controlled Substances Prescription Exception
A commercial driver using hormone replacement therapy qualifies under federal law by satisfying the three-part prescription exception outlined in Title 49. The governing standard sits in 49 CFR 391.41(b)(12)(ii), which states that an individual is qualified if he or she does not use any non-Schedule I drug or substance unless that use is prescribed by a licensed medical practitioner who is familiar with the driver's medical history and has advised the driver that the substance will not adversely affect safe vehicle operation.
This standard functions as a conjunctive, three-part legal test. First, the prescriber must be licensed to prescribe controlled substances. Second, the prescriber must possess familiarity with the driver's medical history. Third, the prescriber must explicitly confirm that the therapy will not impair the driver's ability to safely operate a commercial motor vehicle. Under Appendix A to Part 391 Section J.2, a medical examiner may physically qualify an individual who uses an amphetamine, a narcotic, or another prescribed substance listed on Schedules II through V if this prescription exception is met.
Drug scheduling explains why testosterone qualifies for this exception while other compounds do not. Under 21 CFR 1308.13(f)(84), testosterone is classified as a Schedule III controlled substance under the anabolic steroids category (Drug Enforcement Administration drug code 4000). Schedule I substances cannot be prescribed for any commercial driver under any circumstances, but Schedule III placement makes the prescription exception legally available. The parallel on-duty operating rule in 49 CFR 382.213(b) enforces this identical exception while operating on public roadways.
Federal Drug Testing Panel Limitations and Mandates
Standard workplace drug screens for commercial drivers do not test for testosterone, and testing laboratories are legally forbidden to screen DOT specimens for anabolic steroids. Federal workplace drug testing is governed by Part 40 of Title 49, which establishes strict limits on laboratory analysis.
The regulatory prohibition in 49 CFR 40.82 restricts testing to five specific drug classes. The regulation states that as a laboratory, technicians must test for marijuana metabolites, cocaine metabolites, amphetamines, opioids, and phencyclidine (PCP), and must not test DOT specimens for any other drugs. The omission of testosterone is an affirmative regulatory ban on expanded testing rather than an administrative oversight.
The confirmatory analyte table in 49 CFR 40.85 names fourteen specific substances: THCA, benzoylecgonine, codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, 6-acetylmorphine, phencyclidine, amphetamine, methamphetamine, MDMA, and MDA. A proposed rule published on 2 September 2025 (90 FR 42363) seeks to add fentanyl and norfentanyl to the DOT panel, but that action involves synthetic opioids and includes no anabolic steroids. A standard DOT drug screen cannot detect, confirm, or report testosterone use.
Blood Pressure Evaluation during a TRT and DOT Physical
Elevated blood pressure is the primary clinical finding on hormone therapy that can shorten or interrupt a commercial driver's medical certification. Under 49 CFR 391.41(b)(6), a driver is qualified if he or she has no current clinical diagnosis of high blood pressure likely to interfere with safe commercial driving.
The blood-pressure certification tiers widely circulated across the transportation industry are advisory recommendations rather than statutory mandates. Section I of Appendix A to Part 391 explicitly states that its Medical Advisory Criteria are strictly advisory and do not have the force and effect of law. The Federal Motor Carrier Safety Administration (FMCSA) reaffirmed this standard in the Federal Register (89 FR 3892, 22 January 2024), clarifying that medical examiners remain free to determine whether to utilize advisory guidance in their decision-making. The advisory tiers originate from the 2002 Cardiovascular Advisory Panel Guidelines, which adopted the 1997 sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.
Clinical evidence confirms that exogenous testosterone consistently elevates resting blood pressure. On 28 February 2025, the Food and Drug Administration (FDA) issued class-wide labeling changes requiring warnings that all testosterone products increase blood pressure based on completed ambulatory blood pressure monitoring studies. At the same time, the FDA removed cardiovascular risk language from the Boxed Warning following the TRAVERSE trial, which demonstrated no increase in major adverse cardiovascular events (7.0% in testosterone patients versus 7.3% on placebo) over 36 months.
Pharmaceutical product labeling confirms these hemodynamic effects. The prescribing information for AndroGel 1.62% notes a mean systolic and diastolic blood pressure increase of 1.9 and 1.3 mm Hg across all treated patients, rising to an increase of 3.0 and 2.2 mm Hg in men already taking antihypertensive therapy. The label for injectable Depo-Testosterone explicitly notes that testosterone increases blood pressure and warns against use in patients with uncontrolled hypertension. Blood pressure is therefore the finding most likely to shorten a card on a driver who is otherwise qualified, which is why the advisory tiers below matter more here than any hormone-specific rule. Our page on TRT side effects and risks covers what the labels say about that effect.
| Hypertension stage | Blood pressure reading | Advisory certification period | Recertification conditions | Legal status |
|---|---|---|---|---|
| Stage 1 | 140 to 159 systolic or 90 to 99 diastolic | 1 year | May receive a one-time 3-month certificate if reading remains above 140/90 at renewal | Advisory criterion (Appendix A § E.3) |
| Stage 2 | 160 to 179 systolic or 100 to 109 diastolic | One-time 3-month certificate | Requires initiation or adjustment of antihypertensive treatment; 1 year if reduced to 140/90 or below | Advisory criterion (Appendix A § E.4) |
| Stage 3 | At or above 180 systolic and 110 diastolic | Disqualified until controlled | Must reduce reading to 140/90 or below; certified for 6 months biannually thereafter | Advisory criterion (Appendix A § E.5) |
Hematocrit Standards and Clinical Guidelines
Federal transportation regulations contain no hematocrit limit, red blood cell standard, or mandatory blood draw for commercial drivers. The widespread belief that a hematocrit reading of 54% results in an automatic failure during a DOT examination incorrectly conflates clinical endocrinology stopping rules with federal transportation law.
Under 49 CFR 391.41(b) and the physical examination procedure in 49 CFR 391.43, the only required laboratory test is a dipstick urinalysis screening for specific gravity, protein, blood, and glucose. There is no complete blood count, hemoglobin, or hematocrit requirement anywhere in the federal standard. A high hematocrit can only affect certification indirectly if a medical examiner determines under 49 CFR 391.41(b)(4) or (b)(7) that an active cardiovascular or vascular condition interferes with safe driving.
The 54% threshold originates in clinical guidelines from the Endocrine Society, which treats a hematocrit above 50% as a relative contraindication and a hematocrit above 54% as a reason to stop therapy. The FDA label for AndroGel 1.62% warns of polycythemia in section 5.2, advising prescribers to measure hematocrit prior to treatment, at 3 to 6 months, and annually thereafter. Injectable Depo-Testosterone carries a similar mandate to check hemoglobin and hematocrit periodically.
Hematocrit elevation rates vary significantly depending on the delivery method. A clinical study on erythrocytosis incidence found that polycythemia developed in 66.7% of patients using short-acting injectable testosterone, 35.1% using subcutaneous pellets, and 12.8% using transdermal gels. Furthermore, a 2025 retrospective study of 247 men on hormone therapy published in a 2025 study of testosterone-induced erythrocytosis showed hematocrit rising above 0.46 in 57% of patients, above 0.50 in 23%, and above 0.54 in only 5%. Only 46% of patients who reached 0.46 did so within the first year of therapy, so the majority peaked after year one. Drivers evaluating delivery options can review our comparison of TRT injections vs cream vs pellets and our guide on high hematocrit on TRT to understand how different administration routes impact red cell production.
Examiner Discretion during a TRT and DOT Physical
Certified medical examiners operate with substantial clinical discretion when evaluating drivers using scheduled medications. Because federal regulations do not name testosterone, the examiner must determine whether the driver meets the three-part prescription exception and whether secondary physiological changes compromise safe operation.
Documenting the prescription exception frequently involves supplementary paperwork. Appendix A § J.3 notes that requesting a written communication from the prescribing clinician is one method for the examiner to confirm the exception. The FMCSA provides an optional document, the 391.41 CMV Driver Medication Form (Form MCSA-5895), as a voluntary tool to record prescriber statements. Neither this specific form nor a separate medical clearance letter is mandated by federal statute; the choice to require documentation rests entirely on examiner judgment.
Under 49 CFR 391.43(g)(4), an examiner who requires additional medical information may pend an examination for up to 45 days while the driver collects records. Furthermore, Appendix A § J.4 notes that an examiner may request a non-DOT drug test if clinical indicators suggest undisclosed drug use. While motor carriers may also establish independent policies requiring drivers to report therapeutic medication under 49 CFR 382.213(d), carrier policies represent employer rules rather than federal transportation mandates.
| Regulatory topic | Bright-line federal rule | Medical examiner discretion |
|---|---|---|
| TRT qualification | Schedule III substances are permitted under 49 CFR 391.41(b)(12)(ii) with a valid prescription | The examiner determines whether the prescribing doctor is adequately familiar with the driver's history |
| Mandatory drug panel | Laboratories are prohibited from testing DOT specimens for steroids under 49 CFR 40.82 | The examiner may request a separate, non-DOT drug screen under Appendix A § J.4 if undisclosed use is suspected |
| Blood pressure limits | 49 CFR 391.41(b)(6) requires no clinical diagnosis of high blood pressure interfering with safety | The examiner decides whether to apply the non-binding advisory stages from Appendix A § E |
| Hematocrit testing | No CBC or hematocrit test exists in 49 CFR 391.43 examination requirements | The examiner may request outside laboratory records if symptoms suggest cardiovascular or vascular compromise |
| Prescriber letters | Federal rules require the prescriber to advise that driving is safe, but mandate no specific form | The examiner decides whether to accept a standard letter, require Form MCSA-5895, or pend the exam for 45 days |
Medical Certificate Validity and Expiration Rules
A commercial driver using hormone replacement therapy may receive a standard two-year medical certificate or a shortened certification card depending on secondary health metrics. Under 49 CFR 391.45(b), the maximum qualification interval is 24 months. When a driver presents with well-controlled blood pressure, documented clinical follow-up, and an acceptable physical exam, an examiner may issue the full two-year Medical Examiner's Certificate (Form MCSA-5876).
Shortened certification periods occur when an examiner determines that ongoing clinical monitoring is necessary under Appendix A § F.3. If resting blood pressure falls into advisory Stage 1 or Stage 2 ranges, the examiner will issue a one-year or three-month certificate to track therapeutic response. Drivers initiating therapy can review how long TRT takes to work to understand when physiological markers stabilize.
Regulatory revisions implemented on 23 June 2025 significantly changed the consequences of an exam failure. Under 49 CFR 391.43(g)(3), if an examiner finds a driver not physically qualified, all previously issued medical certificates are immediately invalidated and no longer satisfy commercial driving requirements. A driver can no longer continue operating on an unexpired certificate from an earlier physical after failing a new examination. Furthermore, under 49 CFR 391.43(g)(5)(i)(B), examiners must submit examination results electronically to the FMCSA national registry by midnight local time of the next calendar day.
Mandatory Disclosure and Statutory Falsification Penalties
Federal regulations establish an absolute obligation to disclose all active prescription medications on the driver examination report. While medical examiners exercise clinical discretion regarding qualification, the duty to provide truthful medical history involves zero discretion under federal law. Fire departments run the same arrangement from the other end, where a duty-to-report rule stands in for a hormone panel nobody orders.
Form MCSA-5875 contains a driver certification signature block explicitly linking health history answers to physical qualification standards. By signing, the driver certifies that all provided information is accurate and complete, acknowledging that submitting false or missing information invalidates the examination and certificate. The certification warns that intentionally omitting medical information violates 49 CFR 390.35 and exposes the driver to civil and criminal penalties.
Regulatory penalties for falsification carry substantial financial and legal consequences. Under Appendix B to Part 386 (checked September 2026), knowing falsification of records carries civil penalties up to $15,846 for misrepresenting facts other than reporting violations, recordkeeping penalties up to $1,584 per day to a maximum of $15,846, and general safety violations up to $19,246 per occurrence.
Driver licensing penalties are equally severe. Under 49 CFR 383.73(j), a state licensing agency that determines an applicant falsified medical certification documents must disqualify the individual's commercial learner's permit or CDL for at least 60 consecutive days. If a driver is convicted of fraud related to CDL issuance under § 383.73(k)(1), the state must disqualify the driver for at least one full year. Disclosing a legitimate testosterone prescription carries manageable procedural requirements, while concealing it risks immediate commercial license revocation.
What Documentation the Regulation Contemplates
Appendix A § J.3 describes a written communication from the prescribing practitioner as one way, not the required way, for an examiner to confirm the prescription exception. The FMCSA publishes Form MCSA-5895 as a voluntary, optional tool for recording that information with the driver's consent.
No regulation requires a driver to produce a statement on any particular form, and no regulation requires an examiner to request one. Where an examiner does want more information before deciding, 49 CFR 391.43(g)(4) lets the examination be pended, with the driver told the information must arrive within 45 days and the pending status reported to FMCSA.
The parallel on-duty rule at 49 CFR 382.213(b) applies the same prescriber exception to reporting for or remaining on duty. Separately, 49 CFR 382.213(d) says an employer “may require a driver to inform the employer of any therapeutic drug use”, which is a carrier option rather than a federal mandate on the driver.
Frequently Asked Questions
Does TRT disqualify you from a DOT physical?
Testosterone replacement therapy does not automatically disqualify you from passing a DOT physical. No federal regulation lists testosterone or hypogonadism as disqualifying conditions. Under 49 CFR 391.41(b)(12)(ii), a driver may use prescribed Schedule III controlled substances if a licensed medical practitioner familiar with the driver's medical history confirms the medication does not impair safe vehicle operation. Disqualification occurs only if secondary medical issues, such as severe uncontrolled hypertension or related cardiovascular disease, independently violate physical standards.
Is testosterone on the DOT drug test?
Testosterone is not part of the standard DOT drug test. Under 49 CFR 40.82, certified laboratories are legally prohibited from testing DOT urine specimens for any drugs outside the five required classes: marijuana metabolites, cocaine metabolites, amphetamines, opioids, and phencyclidine. The confirmatory testing table in 49 CFR 40.85 lists fourteen specific chemical analytes, and testosterone appears nowhere on the list. A regulated DOT drug screen cannot detect, confirm, or report anabolic steroids or testosterone therapy.
Do I have to tell the medical examiner I am on TRT?
You must disclose your testosterone prescription on Form MCSA-5875 during your physical examination. The medical history section requires drivers to list all prescription medications, over-the-counter drugs, and herbal supplements. Concealing a prescription violates 49 CFR 390.35, which prohibits fraudulent or intentionally false statements on federal examination records. Falsification can invalidate your medical certificate and subject you to civil penalties up to $15,846 under Appendix B to Part 386, along with mandatory CDL disqualification under 49 CFR 383.73(j).
Can a medical examiner order blood work at a DOT physical?
A certified medical examiner cannot require routine blood work under standard DOT physical rules, but possesses discretionary authority to request records or outside testing if clinical concerns arise. The only mandatory laboratory evaluation required by 49 CFR 391.43 is a dipstick urinalysis checking for specific gravity, protein, blood, and sugar. However, under Appendix A § J.4 and 49 CFR 391.43(g)(4), an examiner who observes clinical signs of cardiovascular strain or undisclosed drug use may pend the exam for up to 45 days to review outside laboratory panels.
What hematocrit level fails a DOT physical?
No hematocrit level fails a DOT physical under federal law because federal transportation regulations contain no hematocrit standard. The widely cited 54% threshold is a clinical stopping rule from the Endocrine Society, not a Department of Transportation regulation. A medical examiner does not draw blood or check red cell counts during a standard evaluation. A high hematocrit reading can only affect certification indirectly if it produces clinically diagnosed vascular or cardiovascular complications that an examiner concludes interfere with driving safety under 49 CFR 391.41(b)(4) or (b)(7).
Will TRT shorten my medical certificate to three months?
Testosterone replacement therapy itself will not shorten your medical card, but secondary blood pressure elevation caused by the therapy can reduce your certification period. If your resting blood pressure falls into advisory Stage 1 (140 to 159 systolic or 90 to 99 diastolic) or Stage 2 (160 to 179 systolic or 100 to 109 diastolic), the examiner may issue a shortened one-year or three-month card under Appendix A § E guidelines to monitor blood pressure response. Drivers with well-controlled blood pressure and complete documentation can receive the full 24-month certificate.
What happens if I do not disclose a prescription on the DOT form?
Omitting a testosterone prescription on Form MCSA-5875 constitutes federal document falsification under 49 CFR 390.35. If the omission is discovered, your Medical Examiner's Certificate becomes invalid immediately. Under Appendix B to Part 386, knowing falsification carries civil penalties up to $15,846. In addition, 49 CFR 383.73(j) mandates that state licensing agencies disqualify your commercial driver's license for at least 60 consecutive days for document fraud, extending to a minimum of one full year if convicted under § 383.73(k)(1).
Does a prescriber letter guarantee certification?
A letter from your prescribing doctor does not guarantee DOT certification. While a letter satisfying 49 CFR 391.41(b)(12)(ii) establishes that the prescription exception is met, the certified medical examiner makes the final legal determination regarding physical qualification. The examiner must evaluate your complete physical examination, resting blood pressure, urinalysis, and cardiovascular health. If secondary physical findings violate federal physical standards, the examiner retains legal authority to disqualify you or issue a shortened certificate regardless of the prescriber's opinion.
Related
- Testosterone replacement therapy side effects and health risks
- Managing elevated hematocrit levels on testosterone replacement therapy
- Comparing testosterone delivery methods and side effect profiles
- Timeline of physiological and clinical changes on testosterone therapy
- Clinical symptoms and diagnostic testing for male hypogonadism
- Review of doctor-led testosterone replacement therapy providers
- TRT and FAA medical certification for pilots